admin – Page 8036 – Get News Story

CD BioSciences Expands Biophysical Analysis to Plant

CD BioSciences is excited to announce its expansion of biophysical analysis services to include plant research.

CD BioSciences, a leading provider of cutting-edge research and development solutions, is excited to announce its expansion of biophysical analysis services to include plant research. With this strategic move, CD BioSciences aims to address the growing demand for innovative biophysical analysis methodologies in plant-related industries.

As the field of plant biology advances, the need for comprehensive and tailored biophysical characterization of plant biomolecules has become increasingly crucial. Plant-based products such as pharmaceuticals, nutraceuticals, and biofuels require thorough analysis throughout their development stages, to ensure their efficacy, safety, and commercial viability. Recognizing this growing industry demand, CD BioSciences has broadened its expertise to assist clients in unlocking the full potential of plant-based technologies.

CD BioSciences’ expanded suite of biophysical analysis tools for plant research covers a wide range of plant biophysical analysis services, including but not limited to:

• Photosynthesis Biophysical Analysis: Using advanced biophysical analytical methods to help global clients characterize the biophysical properties of photosynthetic structures and study the mechanisms of photosynthesis.

• Plant Cell Wall Biophysical Analysis: CD BioSciences provides compositional analysis and structural characterization of plant cell walls, opening up new avenues for elucidating the relationship between structures and functions of the cell walls.

• Pollen Tip Growth Biophysical Analysis: This encompasses a wide range of biophysical analysis services for pollen tip growth, such as pollen hydration rate and pollen viability tests.

• Plant Biomechanics Biophysical Analysis: Combining knowledge and techniques in the field of physics to help researchers perform biophysical analyses of plant biomechanics, including organ and tissue mechanics, growth and morphogenesis, and mechanosensing studies.

CD BioSciences’ expert team strives to integrate forefront discoveries in physics, mathematics, and plant biology. Through this fusion, this company aims to construct a cutting-edge biophysical analysis platform that caters to customers globally by offering various plant analysis services. CD BioSciences’ streamlined process requires customers to solely provide plant samples while their experts handle subsequent tasks such as pre-treating samples, characterizing biophysical properties, and conducting data analysis.

About CD BioSciences

CD BioSciences is one of the world’s leading providers of biophysical assays. Depending upon its biophysical analysis technologies and experience, CD BioSciences can offer tailored service packages for a wide range of project types and scientific questions for all researchers working or interested in protein analysis, protein- and RNA-based drug discovery, or molecular interaction characterization.

Media Contact
Company Name: CD BioSciences
Contact Person: Michelle Moser
Email: Send Email
Country: United States
Website: https://www.cd-biophysics.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: CD BioSciences Expands Biophysical Analysis to Plant

Respiratory Syncytial Virus Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Sanofi, AstraZeneca, Pfizer, GlaxoSmithKline, Bavarian

“Respiratory Syncytial Virus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Respiratory Syncytial Virus, historical and forecasted epidemiology.

DelveInsight’s “Respiratory Syncytial Virus Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Respiratory Syncytial Virus, historical and forecasted epidemiology as well as the Respiratory Syncytial Virus market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Respiratory Syncytial Virus market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Respiratory Syncytial Virus Market Forecast

Some of the key facts of the Respiratory Syncytial Virus Market Report:

The Respiratory Syncytial Virus market size was valued approximately USD 1,200 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
In 2022, the total new cases of RSV (Respiratory Syncytial Virus) observed in the seven major markets (7MM) were approximately 8,495,000, projected to rise by the year 2032.
In 2022, within the EU4 nations, Germany reported the highest count of new RSV cases, approximately 533,000 cases, constituting about 6% of the overall cases across the seven major markets (7MM).
In 2022, Japan reported approximately 983,000 new cases of RSV, with expectations of an increase by 2032.
In 2022, the severity of RSV infection in adults in the US showed that 70% accounted for mild cases, 27% for moderate cases, and 3% for severe cases among the total incident cases of RSV.
Key Respiratory Syncytial Virus Companies: Sanofi/ AstraZeneca, Pfizer, GlaxoSmithKline, Bavarian Nordic, Janssen Research, Moderna, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, AstraZeneca, Gilead Sciences, Pfizer, Alnylam Pharmaceuticals, and others
Key Respiratory Syncytial Virus Therapies: Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others
The Respiratory Syncytial Virus market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Respiratory Syncytial Virus pipeline products will significantly revolutionize the Respiratory Syncytial Virus market dynamics.

Respiratory Syncytial Virus Overview

A common respiratory virus that affects the nose, throat, lungs, and breathing passages is called the respiratory syncytial virus (RSV). Within the family Pneumoviridae and order Mononegavirales, RSV is classified as a member of the genus Orthopneumovirus.

Get a Free sample for the Respiratory Syncytial Virus Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/respiratory-syncytial-virus-rsv-market

Respiratory Syncytial Virus Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Respiratory Syncytial Virus Epidemiology Segmentation:

The Respiratory Syncytial Virus market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Respiratory Syncytial Virus
Prevalent Cases of Respiratory Syncytial Virus by severity
Gender-specific Prevalence of Respiratory Syncytial Virus
Diagnosed Cases of Episodic and Chronic Respiratory Syncytial Virus

Download the report to understand which factors are driving Respiratory Syncytial Virus epidemiology trends @ Respiratory Syncytial Virus Epidemiology Forecast

Respiratory Syncytial Virus Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Respiratory Syncytial Virus market or expected to get launched during the study period. The analysis covers Respiratory Syncytial Virus market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Respiratory Syncytial Virus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Respiratory Syncytial Virus Therapies and Key Companies

Nirsevimab: Sanofi/ AstraZeneca
RSVpreF Vaccine: Pfizer
RSVpreF3 Vaccine: GlaxoSmithKline
MVA-BN RSV Vaccine: Bavarian Nordic
Ad26.RSV.pre F Vaccine: Janssen
mRNA-1345 Vaccine: Moderna
NJ-53718678: Janssen Research & Development
Clesrovimab: Merck Sharp & Dohme LLC
EDP-938: Enanta Pharmaceuticals
MEDI8897: AstraZeneca
GS-5806: Gilead Sciences
RV521: Pfizer
ALN-RSV01: Alnylam Pharmaceuticals

Discover more about therapies set to grab major Respiratory Syncytial Virus market share @ Respiratory Syncytial Virus Treatment Landscape

Respiratory Syncytial Virus Market Strengths

The successful trials of upcoming vaccines namely, RSVPref3, mRNA1345, and RSVPref have displayed the opportunity to change the treatment pattern mainly in the high risk patients i.e. elderly, infants and pregnant women. Further, the approval of these vaccines will proliferate the growth of the overall RSV market.
RSV infection can now be identified quickly due to advances in molecular diagnostics. A new taxonomic nomenclature for RSV was recently accepted, while diagnostic and omics approaches have revealed novel modalities for early detection of RSV infections and better knowledge of disease pathogenesis

Respiratory Syncytial Virus Market Opportunities

RSV highlights the urgent need to develop more cost-effective antiviral preventive strategies, in order to decrease the burden of RSV infections requiring hospitalizations.
Data gaps in the disease burden need to be addressed to understand the epidemiology. Understanding these variances will be critical to establishing cost-effective interventions.
Combining RSV shots with other vaccines like influenza and COVID19 has the potential to offer a comprehensive and more efficient defense against various respiratory viruses.

Scope of the Respiratory Syncytial Virus Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Respiratory Syncytial Virus Companies: Sanofi/ AstraZeneca, Pfizer, GlaxoSmithKline, Bavarian Nordic, Janssen Research, Moderna, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, AstraZeneca, Gilead Sciences, Pfizer, Alnylam Pharmaceuticals, and others
Key Respiratory Syncytial Virus Therapies: Nirsevimab, RSVpreF Vaccine, RSVpreF3 Vaccine, MVA-BN RSV Vaccine, Ad26.RSV.pre F Vaccine, mRNA-1345 Vaccine, NJ-53718678, Clesrovimab, EDP-938, MEDI8897, GS-5806, RV521, ALN-RSV01, and others
Respiratory Syncytial Virus Therapeutic Assessment: Respiratory Syncytial Virus current marketed and Respiratory Syncytial Virus emerging therapies
Respiratory Syncytial Virus Market Dynamics: Respiratory Syncytial Virus market drivers and Respiratory Syncytial Virus market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Respiratory Syncytial Virus Unmet Needs, KOL’s views, Analyst’s views, Respiratory Syncytial Virus Market Access and Reimbursement

To know more about Respiratory Syncytial Virus companies working in the treatment market, visit @ Respiratory Syncytial Virus Clinical Trials and Therapeutic Assessment

Table of Contents

1. Respiratory Syncytial Virus Market Report Introduction

2. Executive Summary for Respiratory Syncytial Virus

3. SWOT analysis of Respiratory Syncytial Virus

4. Respiratory Syncytial Virus Patient Share (%) Overview at a Glance

5. Respiratory Syncytial Virus Market Overview at a Glance

6. Respiratory Syncytial Virus Disease Background and Overview

7. Respiratory Syncytial Virus Epidemiology and Patient Population

8. Country-Specific Patient Population of Respiratory Syncytial Virus

9. Respiratory Syncytial Virus Current Treatment and Medical Practices

10. Respiratory Syncytial Virus Unmet Needs

11. Respiratory Syncytial Virus Emerging Therapies

12. Respiratory Syncytial Virus Market Outlook

13. Country-Wise Respiratory Syncytial Virus Market Analysis (2019–2032)

14. Respiratory Syncytial Virus Market Access and Reimbursement of Therapies

15. Respiratory Syncytial Virus Market Drivers

16. Respiratory Syncytial Virus Market Barriers

17. Respiratory Syncytial Virus Appendix

18. Respiratory Syncytial Virus Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Respiratory Syncytial Virus Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Sanofi, AstraZeneca, Pfizer, GlaxoSmithKline, Bavarian

HR Positive HER Negative Breast Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Eli Lilly and Company, Laekna Limited, Sermonix

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, HR Positive HER Negative Breast Cancer pipeline constitutes 50+ key companies continuously working towards developing 53+ HR Positive HER Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The HR Positive HER Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“HR Positive HER Negative Breast Cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HR Positive HER Negative Breast Cancer Market.

Some of the key takeaways from the HR Positive HER Negative Breast Cancer Pipeline Report:

Companies across the globe are diligently working toward developing novel HR Positive HER Negative Breast Cancer treatment therapies with a considerable amount of success over the years.
HR Positive HER Negative Breast Cancer companies working in the treatment market are Seagen Inc., Regor Pharmaceuticals, Verastem Oncology, Olema Pharmaceuticals, Inc, Tyme, Inc., EOC Pharma, CytomX Therapeutics, Daiichi Sankyo, Inc., AstraZeneca, Chia Tai Tianqing Pharmaceutical Group, and others, are developing therapies for the HR Positive HER Negative Breast Cancer treatment

Emerging HR Positive HER Negative Breast Cancer therapies in the different phases of clinical trials are- SGN-B7H4V, RGT-419B, Abemaciclib + VS-6766 + Fulvestrant, OP-1250, SM-88, EOC202, CX-2009, Dato-DXd, Camizestrant + Palbociclib, TQB3616, and others are expected to have a significant impact on the HR Positive HER Negative Breast Cancer market in the coming years.
In September 2023, The initial positive outcomes from the TROPION-Breast01 Phase III trial indicated that datopotamab deruxtecan (Dato-DXd) showed a statistically notable and clinically meaningful improvement in the primary metric of progression-free survival (PFS) compared to the investigator-selected chemotherapy. These results were evident among patients managing inoperable or metastatic hormone receptor (HR)-positive, HER2-low, or negative (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer, previously treated with endocrine-based therapy and at least one systemic therapy.
In January 2023, Context Therapeutics Inc., a company dedicated to pioneering innovative therapies for solid tumors, particularly focusing on female-related cancers, announced that its clinical trial partner, Stemline Therapeutics, Inc., a wholly owned subsidiary of The Menarini Group (“Menarini”), obtained FDA approval for ORSERDU (elacestrant). This approval targets the treatment of postmenopausal women or adult men dealing with estrogen receptor–positive (ER+), HER2-negative (HER2-), and Estrogen Receptor 1 gene (ESR1)-mutated advanced or metastatic breast cancer. ORSERDU is intended for individuals experiencing disease progression following at least one line of endocrine therapy.
On January 27, 2023, The FDA has granted approval for elacestrant (Orserdu) to treat individuals with advanced or metastatic breast cancer who are postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated conditions. This approval is specifically for those patients who have experienced disease progression after undergoing at least one round of endocrine therapy.
In January 2023, ENHERTU® (trastuzumab deruxtecan) by Daiichi Sankyo and AstraZeneca has received approval in the European Union (EU) as a standalone therapy. It is intended for adult patients dealing with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer. These patients should have undergone previous chemotherapy in the metastatic setting or experienced disease recurrence either during or within six months after completing adjuvant chemotherapy.
In February 2023, Gilead Sciences’ Trodelvy, newly approved by the FDA, has made a significant entry into the breast cancer arena, which is pivotal for the drug’s commercial success and the broader oncology aspirations of the company. Gilead announced the FDA approval of Trodelvy for previously treated HR-positive, HER2-negative breast cancer. Patients eligible for this therapy must have undergone endocrine therapy and received at least two additional therapies in the metastatic setting. Trodelvy had previously obtained approval for treating triple-negative breast cancer. However, the HR-positive, HER2-negative disease encompasses a considerably larger patient group, constituting approximately two-thirds of all breast cancer cases.

HR Positive HER Negative Breast Cancer Overview

If the cells in a breast cancer have estrogen and progesterone receptors, the cancer cells may be receiving signals from these hormones that encourage cell proliferation. This is known as an HR-positive diagnosis. Additionally, HER-2 proteins, or receptors, which aid in regulating the growth and repair of breast cells, are examined in cancer tissue. Because HER-2-negative breast cancers have cells with little to no HER-2 protein, they grow more slowly and generally have a better prognosis than HER-2-positive cancers.

Get a Free Sample PDF Report to know more about HR Positive HER Negative Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/hr-positive-her2-negative-breast-cancer-pipeline-insight

Emerging HR Positive HER Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:

SGN-B7H4V: Seagen Inc.
RGT-419B: Regor Pharmaceuticals
Abemaciclib + VS-6766 + Fulvestrant: Verastem Oncology
OP-1250: Olema Pharmaceuticals, Inc
SM-88: Tyme, Inc.
EOC202: EOC Pharma
CX-2009: CytomX Therapeutics
Dato-DXd: Daiichi Sankyo, Inc.
Camizestrant + Palbociclib: AstraZeneca
TQB3616: Chia Tai Tianqing Pharmaceutical Group

HR Positive HER Negative Breast Cancer Route of Administration

HR Positive HER Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal

HR Positive HER Negative Breast Cancer Molecule Type

HR Positive HER Negative Breast Cancer Products have been categorized under various Molecule types, such as

Oligonucleotide
Peptide
Small molecule

HR Positive HER Negative Breast Cancer Pipeline Therapeutics Assessment

HR Positive HER Negative Breast Cancer Assessment by Product Type
HR Positive HER Negative Breast Cancer By Stage and Product Type
HR Positive HER Negative Breast Cancer Assessment by Route of Administration
HR Positive HER Negative Breast Cancer By Stage and Route of Administration
HR Positive HER Negative Breast Cancer Assessment by Molecule Type
HR Positive HER Negative Breast Cancer by Stage and Molecule Type

DelveInsight’s HR Positive HER Negative Breast Cancer Report covers around 53+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further HR Positive HER Negative Breast Cancer product details are provided in the report. Download the HR Positive HER Negative Breast Cancer pipeline report to learn more about the emerging HR Positive HER Negative Breast Cancer therapies

Some of the key companies in the HR Positive HER Negative Breast Cancer Therapeutics Market include:

Key companies developing therapies for HR Positive HER Negative Breast Cancer are – Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., BeiGene, Olema Pharmaceuticals, AstraZeneca, Radius Health, Adagene Inc, H3 Biomedicine Inc., Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Tyme, Inc., PIQUR Therapeutics, Pfizer, Merus N.V., Seagen, Relay Therapeutics, Inc., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, InventisBio Co., Ltd, Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Modra Pharmaceuticals, MedImmune LLC, QED Therapeutics, Inc., Blueprint Medicines Corporation, TransThera Sciences (Nanjing), Inc., HUTCHMED, VelosBio Inc., Dantari, Inc., GlaxoSmithKline, G1 Therapeutics, Inc., and others.

HR Positive HER Negative Breast Cancer Pipeline Analysis:

The HR Positive HER Negative Breast Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of HR Positive HER Negative Breast Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HR Positive HER Negative Breast Cancer Treatment.
HR Positive HER Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
HR Positive HER Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HR Positive HER Negative Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about HR Positive HER Negative Breast Cancer drugs and therapies

HR Positive HER Negative Breast Cancer Pipeline Market Drivers

Rising incidence of Breast Cancer, increase in Research and Development activities are some of the important factors that are fueling the HR Positive HER Negative Breast Cancer Market.

HR Positive HER Negative Breast Cancer Pipeline Market Barriers

However, high cost associated with the treatment, side effects associated with the treatment and other factors are creating obstacles in the HR Positive HER Negative Breast Cancer Market growth.

Scope of HR Positive HER Negative Breast Cancer Pipeline Drug Insight

Coverage: Global
Key HR Positive HER Negative Breast Cancer Companies: Seagen Inc., Regor Pharmaceuticals, Verastem Oncology, Olema Pharmaceuticals, Inc, Tyme, Inc., EOC Pharma, CytomX Therapeutics, Daiichi Sankyo, Inc., AstraZeneca, Chia Tai Tianqing Pharmaceutical Group, and others
Key HR Positive HER Negative Breast Cancer Therapies: SGN-B7H4V, RGT-419B, Abemaciclib + VS-6766 + Fulvestrant, OP-1250, SM-88, EOC202, CX-2009, Dato-DXd, Camizestrant + Palbociclib, TQB3616, and others
HR Positive HER Negative Breast Cancer Therapeutic Assessment: HR Positive HER Negative Breast Cancer current marketed and HR Positive HER Negative Breast Cancer emerging therapies
HR Positive HER Negative Breast Cancer Market Dynamics: HR Positive HER Negative Breast Cancer market drivers and HR Positive HER Negative Breast Cancer market barriers

Request for Sample PDF Report for HR Positive HER Negative Breast Cancer Pipeline Assessment and clinical trials

Table of Contents

1. HR Positive HER Negative Breast Cancer Report Introduction

2. HR Positive HER Negative Breast Cancer Executive Summary

3. HR Positive HER Negative Breast Cancer Overview

4. HR Positive HER Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. HR Positive HER Negative Breast Cancer Pipeline Therapeutics

6. HR Positive HER Negative Breast Cancer Late Stage Products (Phase II/III)

7. HR Positive HER Negative Breast Cancer Mid Stage Products (Phase II)

8. HR Positive HER Negative Breast Cancer Early Stage Products (Phase I)

9. HR Positive HER Negative Breast Cancer Preclinical Stage Products

10. HR Positive HER Negative Breast Cancer Therapeutics Assessment

11. HR Positive HER Negative Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. HR Positive HER Negative Breast Cancer Key Companies

14. HR Positive HER Negative Breast Cancer Key Products

15. HR Positive HER Negative Breast Cancer Unmet Needs

16 . HR Positive HER Negative Breast Cancer Market Drivers and Barriers

17. HR Positive HER Negative Breast Cancer Future Perspectives and Conclusion

18. HR Positive HER Negative Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Navdha Goel
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HR Positive HER Negative Breast Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Eli Lilly and Company, Laekna Limited, Sermonix

Trucking42 Launches New Services for Trucking Companies in USA

Trucking42 is an innovative platform that revolutionizes the trucking industry by integrating technology to streamline logistics operations. It offers a comprehensive suite of services, including freight matching, load booking, tracking, and payment solutions. Using advanced algorithms and AI, Trucking42 efficiently connects shippers with carriers, optimizing routes and reducing empty miles, which ultimately boosts efficiency and reduces costs.

Miami, FL – December 13, 2023 – Trucking42 a leading provider of truck dispatch service for trucking companies in USA and logistics services, announced today the launch of new services for trucking companies in the USA. The new services include safety and compliance, IFTA, accounting and administration, hiring drivers, and car hauler dispatch.

Trucking42 aims to help trucking companies improve their efficiency, profitability, and safety by offering full-service solutions that cover every aspect of their operations. Trucking42 has a team of experienced and professional dispatchers, who are responsible for booking loads, negotiating rates, building routes, and assisting drivers 24/7. Trucking42 also offers safety and compliance services, such as MC registration, ELD management, and FMCSA rules adherence, to help trucking companies avoid fines and violations. Additionally, Trucking42 provides IFTA services, accounting and administration services, hiring drivers services, and car hauling dispatch services for both open and enclosed carriers.

Trucking42 has been serving the trucking industry since 2018, and has grown to handle over 200 active trucks and generate over $120 million in client gross per month. Trucking42 has a network of over 50 MC clients, most of whom started with one truck only and grew to big size fleets with the help of Trucking42. Trucking42 has also received positive feedback and testimonials from its clients, who appreciate its professionalism, transparency, and results.

Trucking42, Inc. is a Miami-based company that provides truck dispatch and logistics services for freight motor carriers in the USA. Trucking42 offers full-service solutions, including booking loads, negotiating rates, building routes, assisting drivers, safety and compliance, IFTA, accounting for trucking companies and administration, hiring drivers, and car hauling dispatch. Trucking42 has a team of experienced and professional dispatchers, who are available 24/7 to support its clients. Trucking42 aims to help trucking companies improve their efficiency, profitability, and safety for trucking companies by offering the best solutions and support.

Media Contact
Company Name: Trucking42
Contact Person: Alex
Email: Send Email
Phone: +1(321)-329-8142
City: Miami
State: Florida
Country: United States
Website: https://trucking42.com

ProServeIT Corporation Secures Exclusive Invitation to Microsoft’s Groundbreaking Copilot for Microsoft 365 Jumpstart Partner Initiative

ProServeIT Corporation, a renowned IT consulting and managed services provider, proudly announces its exclusive invitation to join Microsoft’s Copilot for Microsoft 365 Jumpstart Partner Initiative. This prestigious invitation, extended only to partners with a proven track record in Microsoft 365-based solutions, solidifies ProServeIT’s standing as a leader in the industry.

With strong customer signals indicating high demand for Copilot for Microsoft 365, Microsoft has strategically invited ProServeIT to collaborate on this initiative. ProServeIT is among the pioneering partners chosen to participate in this unique opportunity, highlighting its commitment to delivering cutting-edge solutions.

“We are honored to be among the select partners invited to Microsoft’s Copilot for Microsoft 365 Jumpstart initiative. This collaboration not only strengthens our relationship with Microsoft but also underscores our commitment to providing innovative solutions that meet the evolving needs of our clients. We look forward to leveraging this opportunity to drive mutual success and deliver exceptional value to our customers.” said President of ProServeIT, Eric Sugar.

The Copilot for Microsoft 365 Jumpstart initiative aims to foster collaboration between partners and Microsoft teams to capitalize on the growing demand for Copilot for Microsoft 365. ProServeIT will gain access to key resources and investments, including Copilot for Microsoft 365 seats, technical and go-to-market guidance, product roadmap briefings, and high-propensity customer leads.

ProServeIT commits to driving sales of seats for Copilot for Microsoft 365, sharing and tracking joint pipelines in the Microsoft Partner Center, training sales and technical resources on Copilot for M365, creating a go-to-market strategy, building and publishing Copilot offers in Microsoft’s commercial marketplace, and participating in case studies and webinars.

About ProServeIT Corporation

Established in 2002, ProServeIT Corporation was one of the first Microsoft Partners to spearhead the adoption of Cloud computing. As a modern IT specialist and trusted technology advisor, ProServeIT continues to help organizations in various industries unlock their digital future and turn technology into a true business enabler. ProServeIT is headquartered in Oakville, Ontario, with offices in Prince Edward Island (Canada), Illinois (United States), New Mexico (United States), Paris (France), and Ho Chi Minh City in southern Vietnam. ProServeIT is a people-first organization, and its employees aim to live out its three core values on a daily basis: People Matter. Be Like Gumby. Do It Right. Your success matters to us. Partner with ProServeIT and unlock your organization’s digital future.

Media Contact
Company Name: ProServeIT
Contact Person: Bryan Hynes
Email: Send Email
Country: United States
Website: https://proserveit.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: ProServeIT Corporation Secures Exclusive Invitation to Microsoft\’s Groundbreaking Copilot for Microsoft 365 Jumpstart Partner Initiative

Experts at RFA Cancellation Help Families Across America Reclaim Financial Freedom

“”Thousands of families find themselves stuck in unwanted, costly timeshares. Now, with RFA Cancellation, they can break free.” – Haley Simmoneau, Esq.”

Nevada – December 13, 2023 – For families with a passion for travel, investing in a timeshare might appear to be a wise financial choice. Regrettably, timeshares have become one of the most misrepresented vacation products, often pushing families into financial turmoil without ever enjoying the promised benefits. Timeshares, touted as a way for families to savor vacations in their preferred resorts or affiliated locations for a typical week-long stay, frequently disappoint. Families often encounter denials of access to the purchased unit or find themselves unable to book dates that suit their needs. Unfortunately, numerous timeshare resort developers resort to high-pressure, deceptive, and even fraudulent tactics to persuade unsuspecting families into buying a high-priced product that doesn’t live up to its promises. In most instances, these families are unaware that they are entering a lifetime commitment that could impact their estate and bind their heirs to inherit the contract, along with its associated fees and expenses. This is where the experts in timeshare contract cancellations at RFA Cancellation come to the rescue, saving families their hard-earned money.

This team of legal experts specializes in timeshare contract cancellations, exclusively serving timeshare owners who were deceived about the reality of ownership. “Thousands of families find themselves stuck in unwanted, costly timeshares. Now, with RFA Cancellation, they can break free.” – Haley Simmoneau, Esq.

These seasoned professionals focus on the niche legal field of timeshare cancellations, employing consumer protection, real estate, and contract law to terminate timeshare contracts. Their services extend across various resorts in the United States, Mexico, and the Caribbean.

Leveraging their expertise, RFA Cancellation guides clients through a systematic process to release themselves from the shackles of timeshare ownership. Before initiating a case, these attorneys encourage clients to explore options such as returning the timeshare to the resort developers or attempting to sell it. In cases where these endeavors prove fruitless, the legal team at RFA Cancellation conducts a comprehensive review of all documents related to the timeshare purchase, thoroughly assessing the circumstances surrounding each prospective client’s case. The best part is that this initial evaluation is provided at no cost. RFA Cancellation only takes on cases when they are highly confident in the facts, ensuring not only 100% client satisfaction but also the assurance of an affordable, one-time fixed fee.

Recognizing the unparalleled challenges faced by their clients worldwide, RFA Cancellation has introduced an affordable payment solution through their Stimulus Dollars Discount program, offering financial relief.

Take the definitive step towards breaking free from the financial burdens of timeshare ownership with RFA Cancellation. Visit their website at https://www.rfacancellation.com

About the Firm

The legal professionals at RFA Cancellation are dedicated to assisting timeshare owners. They leverage consumer protection, real estate, and contract law to terminate timeshare contracts, relieving clients of their financial obligations.

Media Contact
Company Name: RFA Cancellation
Contact Person: Karen Sargent
Email: Send Email
Phone: (888)-602-1735
Address:20715 North Pima Road Suite, 108
City: Scottsdale
State: AZ
Country: United States
Website: www.rfacancellation.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Experts at RFA Cancellation Help Families Across America Reclaim Financial Freedom

Revolutionizing Amazon Stores: Reez Media’s Winning Approach

Reez Media, co-founded by Stephen Rozo and Joe Reeves, is making waves in the world of Amazon selling. The duo are using their firsthand knowledge of growing multi-million dollar online brands to help other sellers grow their stores.

REEZ MEDIA – A boutique Amazon agency, Reez Media, co-founded by Stephen Rozo and Joe Reeves, is changing the way Amazon sellers are running their business. Specializing in growing Amazon stores, the agency goes beyond basics to help brands find success on the marketplace.

Having navigated the challenges of selling on Amazon firsthand, the duo recognized the need for expert guidance in the market. Driven by their journey from successful online entrepreneurs to the leaders of Reez Media, the agency is committed to offering Amazon sellers cutting-edge solutions for running thriving stores.

Joe Reeves, one of the driving forces behind Reez Media, shares, “My journey from successful Amazon seller to agency owners has been fueled by a passion for helping other brands navigate the Amazon marketplace. We understand the challenges because we’ve faced them ourselves. Reez Media is more than an agency; it’s a partner for brands seeking to maximize their potential on Amazon.”

Stephen Rozo, co-founder of Reez Media, adds, “We founded Reez Media with the vision of creating a comprehensive solution for brands looking to thrive on Amazon. Our hands-on approach, combined with data-driven strategies, sets us apart in the digital marketing landscape. We’re here to empower brands and guide them toward lasting success.”

Rooted in a commitment to transparency, innovation, and client success, Reez Media provides a full suite of services. This includes advanced PPC advertising, data-driven optimizations, and hands-on support, helping brands to achieve their goals on Amazon.

By blending insider knowledge with cutting-edge advertising strategies, Reez Media aims to be the catalyst for brands not only surviving but thriving in the fiercely competitive online retail landscape. As the agency continues to flourish, the co-founders and the Reez Media team remain dedicated to sharing their expertise and helping brands unlock the full potential of their presence on Amazon.

About Reez Media

Reez Media, co-founded by Stephen Rozo and Joe Reeves, is a boutique advertising agency specializing in rapidly growing Amazon stores. Leveraging a seasoned team, firsthand expertise, and proven strategies, the agency helps brands reach their maximum potential on Amazon.

Media Contact
Company Name: Reez Media
Contact Person: Stephen Rozo
Email: Send Email
Country: United States
Website: reezmedia.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Revolutionizing Amazon Stores: Reez Media\’s Winning Approach

“Unlocking Potential: Emerging Growth’s Rising Stars Look Now! ASPI, VTAK, INBS, HNRC

ASP Isotopes Inc. (NASDAQ: ASPI) is a pre-commercial stage advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”). The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes). There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. Watch ASPI’s Parker Scott at Emerging Growth Here

Catheter Precision, Inc. (NYSE American: VTAK), a cutting-edge medical technology firm, revealed on December 5 that it had received an invitation to present at the Emerging Growth Conference scheduled for December 6, 2023. During the event, Catheter Precision will spotlight its groundbreaking non-invasive 3D mapping system, VIVO™, designed to assist physicians in pinpointing the source of ventricular arrhythmias before medical procedures while enhancing workflow efficiency and shortening procedure durations. This cost-effective and innovative remedy has obtained regulatory approval from the United States Food and Drug Administration (FDA) and is currently accessible for commercial use in Europe.

Watch VTAK’s David Jenkins at Emerging Growth Here

Furthermore, VIVO™ 3D Mapping System’s revolutionary potential was recently featured by “Cardiac Rhythm News” see complete news article: https://cardiacrhythmnews.com/catheter-precisions-vivo-3d-mapping-system-secures-reimbursement-in-nhs-englands-ssdp/

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a life sciences company. The Company is engaged in developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It operates through two segments, namely Commercially available Intelligent Fingerprinting Products (IFPG) and Development Stage Saliva Glucose Biosensor Platform (SGBP). Its product portfolio includes a portable drug screening system that works by analyzing fingerprint sweat using a one-time cartridge and portable handheld reader and also includes a development stage range of biosensor- based Point of Care diagnostic tests (POCT) that are developed in the modalities of clinical chemistry, immunology, tumor markers, allergens, and endocrinology. Its product candidate is the Saliva Glucose Biosensor (SGB), a POCT expected to substitute the finger pricking invasive blood glucose monitoring for diabetic patients. Its Biosensor Platform helps to detect multiple biological analytes. Watch INBS’Harry Simeonidis, President / CEO at Emerging Growth Here

Houston Natural Resources Corp (OTC: HNRC) stands as a versatile energy enterprise with stakes in both oil and gas. Notably, the company has successfully obtained full ownership, a 100% interest, in Cunningham Energy LLC, boasting appraised reserves totaling $352 million. Additionally, Houston Natural Resources Corp holds minority investments in Rhino Energy Ltd, CE Energy Sponsors, LLC, and HNR Acquisition Corp. The company encompasses mining ventures in copper, lithium, gold, as well as other valuable and rare earth metals. With a global perspective, the investment strategy is underpinned by a commitment to sustainability, making it an integral element of the company’s core approach. Demonstrating a commitment to growth, the company remains proactive in its pursuit of new opportunities within the energy and energy transitions sectors, all with the overarching goal of delivering enhanced value to its shareholders. Watch HNRC’s Frank Kristan, Chairman & CEO at Emerging Growth Here

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: \”Unlocking Potential: Emerging Growth\’s Rising Stars Look Now! ASPI, VTAK, INBS, HNRC

Top Realtor Agent In Montrose, CA, Shares Insights On Maximizing Home Equity

Home equity is the amount of the mortgage paid outside of the interest. Many times this equity is a valuable tool for home repairs and other major purchases. Knowing how to maximize this equity is important for any home owner, especially when the home is going onto the market for sale.

Vic Markarian is a real estate listing agent in Montrose, California. He has been in the real estate industry for almost four decades and the skills to help sellers maximize the equity in a home sale.

“The agent the home seller selects is absolutely vital to the best possible deal and equity. Too often I have clients coming to me because of a bad experience with another real estate selling agent here in Montrose, CA,” said Markarian.

Markarian always makes sure to get the best possible deal for the seller and for the buyer. His goal is to make both feel as if they came out ahead, even without knowing the other side of the deal.

“I have sellers who have commented they did not feel as if there was a commission on the sale because their property sold at such a high cost. This is my goal as their agent,” continued Markarian.

In addition to his extensive experience, Vic Markarian also stays updated on the latest market trends and employs cutting-edge marketing strategies to ensure that his clients’ properties receive maximum exposure. His dedication to excellence and commitment to client satisfaction have earned him a stellar reputation in the Montrose real estate community.

Vic Markarian is among the best Realtors in Montrose, CA. With a proven track record and over 34 years in the business, Markarian and his team can move properties where others have not. Learn more at the website. Visit http://markarianrealty.com/ and https://www.vicmarkarian.com/ for more.

Media Contact
Company Name: Vic Markarian Realty Group
Contact Person: Media Relations
Email: Send Email
Phone: +1 818 248 8668
Address:3237 N Verdugo Rd
City: Montrose
State: California 91208
Country: United States
Website: http://MarkarianRealty.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Realtor Agent In Montrose, CA, Shares Insights On Maximizing Home Equity

FreeCast Adds Five Free Sports Channels from acTVe

FAST channels for surfing, skateboarding, bicycling, skiing, and snowboarding join FreeCast’s lineup.

FreeCast is announcing a partnership with acTVe, bringing five sports-focused channels to the company’s collection of over 700 free streaming channels. Each channel is based on one of The Arena Group’s iconic brands: Surfer Magazine, Powder Magazine, Transworld Skateboarding, Bike Mag and Snowboarder and provides robust content from each of the action sports and lifestyle verticals.

Surfer comes from the renowned magazine of the same name, known as the “Bible of surfing” since 1960. Powder is the most trusted name in skiing, covering every aspect of the sport. Skate features content from Transworld Skateboarding, the biggest skateboarding brand in the world. Bike Mag showcases the sport of mountain biking like no other channel can. Snowboarder is the ultimate authority on snowboard culture.

These channels showcase an extensive collection of exclusive premium content sourced from the robust libraries of these renowned brands. Viewers can expect thousands of hours of content including documentary features, shorts, original series, live events, and much more. “These channels will deliver the ultimate sports experience, representing the very best each sport has to offer through the backing of their respective premier brands – a truly exceptional blend,” remarked Geoff Clark, CEO of acTVe.

FreeCast’s Executive Vice President of Digital Content, Tracy West, talked about the broad appeal of these sports channels. “These channels are special because they deal with the types of sports that their viewers actively participate in. In mountainous parts of the country, skiing and snowboarding are part of the culture. In Florida and California, surfing is more than just a pastime for many. That gives these channels a real connection with their audiences and with whole parts of the country.”

Media Contact
Company Name: FreeCast Inc.
Contact Person: Kevin Speedy
Email: Send Email
Phone: (407) 374-1607
Address:6901 TPC Drive Suite 200
City: Orlando
State: Florida
Country: United States
Website: https://freecast.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: FreeCast Adds Five Free Sports Channels from acTVe